Evaluation of olive leaf extract in obese women on weight-loss diet

Evaluation of olive leaf extract on weight and body composition, free fatty acid, glycemic factors, lipid profile and serum level of adipocytokines in obese women on a weight-loss diet

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190129042552N2

Enrollment

Registered

2020-05-30

Start date

2020-06-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Obesity due to excess calories

Interventions

Intervention 1: Intervention group: Daily intake of 250 mg olive leaf extract as 2 pills and weight loss diet. Intervention 2: Control group: Daily intake of 250 mg placebo as 2 pills and weight loss

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Women aged 18-50 years Body mass index 30-40 kg/m2

Exclusion criteria

Exclusion criteria: Menopause Pregnancy and breast feeding Food allergy Having a history of cancer, acute or chronic renal Failure, acute or chronic hepatic failure, thyroid disorder and gastrointestinal diseases Having surgical operation to weight loss Having weight loss over the past six months Consumption of multivitamin/mineral supplements, herbal supplements or weight-loss drugs Don’t use more than 10% of medications

Design outcomes

Primary

Measure	Time frame
Body weight. Timepoint: Before, after 4 and 8 weeks. Method of measurement: Scale.;Body composition. Timepoint: Before, 4 weeks and 8 weeks after intervention. Method of measurement: Bioelectrical impedance analysis.;Serum level of free fatty acid. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA.;Fasting blood sugar (FBS). Timepoint: Before and 8 months after intervention. Method of measurement: Colorimetric enzymatic method (Pars Azmun).;Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). Timepoint: Before and 8 months after intervention. Method of measurement: HOMA-IR: [fasting insulin Mu/ml × fasting glucose mg/dl]/405.;Lipid profile. Timepoint: Before and 8 months after intervention. Method of measurement: Colorimetric enzymatic method (Pars Azmun).;Serum level of leptin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA.;Serum level of adiponectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA.	—

Measure

Time frame

Body weight. Timepoint: Before, after 4 and 8 weeks. Method of measurement: Scale.;Body composition. Timepoint: Before, 4 weeks and 8 weeks after intervention. Method of measurement: Bioelectrical impedance analysis.;Serum level of free fatty acid. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA.;Fasting blood sugar (FBS). Timepoint: Before and 8 months after intervention. Method of measurement: Colorimetric enzymatic method (Pars Azmun).;Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). Timepoint: Before and 8 months after intervention. Method of measurement: HOMA-IR: [fasting insulin Mu/ml × fasting glucose mg/dl]/405.;Lipid profile. Timepoint: Before and 8 months after intervention. Method of measurement: Colorimetric enzymatic method (Pars Azmun).;Serum level of leptin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA.;Serum level of adiponectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShayesteh

Ahvaz University of Medical Sciences

Forough_shayesteh@yahoo.com+98 61 3373 8253

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 16, 2026